Flupentixol & Melitracen

Flupentixol & Melitracen

™ Flupentixol & Melitracen FMR Composition: FMR™ Tablet: Each film coated tablet contains Flupentixol Dihydrochloride BP equivalent to Flupentixol 0.5 mg & Melitracen Hydrochloride INN equivalent to Melitracen 10 mg. Description: FMR™ (Flupentixol & Melitracen combination) acts as antipsychotic drug; also acts as an antidepressant when used in low dose. Flupenthixol is a dopamine D1 & dopamine D2 receptors antagonist, which stops the neurotransmitter binding to its receptor sites and Melitracen is a nor-adrenalin and serotonin reuptake inhibitor at the synapse in the brain. Flupenthixol is an anti-depressive drug with anxiolytic properties. Melitracen is a bipolar thymoleptic with activating properties. This combination renders an excellent mood stabilizing effect with antidepressant, anxiolytic and activating properties. Indications: FMR™ is indicated in the treatment of various types of anxiety, depression, and apathy. Maintenance in Psychogenic depression, dysphoria, depression in alcoholics, drug-addicts and other psychoses. Dosage & Administration: Adults: Usually 2 tablets daily; morning and noon. In severe cases the morning dose may be increased to 2 tablets. Elderly patients: 1 tablet in the morning. Maintenance dose: Usually 1 tablet in the morning. In case of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended. Children: Not recommended. OR AS DIRECTED BY THE PHYSICIAN. Side Effects: In the recommended doses side-effects are rare. These could be transient restlessness and insomnia. Precautions: If previously the patient has been treated with tranquilizers with sedative effects these should be withdrawn gradually. Pregnancy: Not recommended. Lactation: Not recommended. Contraindications: The immediate recovery phase after myocardial infarction, Defects in bundle-branch conduction, untreated narrow angle glaucoma, acute alcohol, barbiturate and opiate intoxication. It should not be given to patients who have received a MAO-inhibitor within two weeks. Not recommended for excitable or overactive patient since its activating effect may lead to exaggeration of these characteristics. Drug Interaction: Flupentixol-melitracen may enhance the response to alcohol, barbiturates and other CNS depressants. Simultaneous administration of MAO-inhibitors may cause hypertensive crises. Storage Condition: Store in a cool & dry place below 300 C, protect from light. Keep out of the reach of children. Presentation: FMR™ Tablet: Each box contains 5 X 10’s tablets in blister pack. .

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    2 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us